AeroLeads people directory · profile
Alvin Luk Email & Phone Number
Co-Founder and CEO
at
HuidaGene Therapeutics
1 work email found
@peoplepc.com
2 phones found area 415
LinkedIn matched
✓ Verified Jun 2026
4 data sources
Profile completeness 100%
Current company
Role
Co-Founder and CEO
Location
New York, New York, United States
Who is Alvin Luk? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Alvin Luk is listed as Co-Founder and CEO at HuidaGene Therapeutics, based in New York, New York, United States. AeroLeads shows a work email signal at peoplepc.com, phone signal with area code 415, and a matched LinkedIn profile for Alvin Luk.
Alvin Luk previously worked as Member of Scientifc Advisory Board at Huidagene Therapeutics and Member Board of Directors at Huidagene Therapeutics. Alvin Luk holds Master Of Business Administration - Mba, Business Administration from Harvard Business School.
Company email context
Email format at HuidaGene Therapeutics
This section adds company-level context without repeating Alvin Luk's masked contact details.
{first}.{last}@peoplepc.com
86% confidence
AeroLeads found 1 current-domain work email signal for Alvin Luk. Compare company email patterns before reaching out.
Profile bio
About Alvin Luk
With over three decades of global drug development experience in small, mid-sized, and large public or private biotech/biopharma organizations, I am a visionary leader and a passionate advocate for rare diseases and gene therapy. As the co-founder and CEO of HuidaGene Therapeutics, I oversee the discovery, engineering, and development of CRISPR-based gene-editing tools and gene therapies to treat various disorders, such as CNS, ophthalmology, myology, otology, and hepatology. I have a proven track record of participating in more than 250 regulatory submissions and leading successful regulatory negotiations, clinical trials, and successful commercial launches of 21 approved products in multiple regions, including the USA, Canada, Europe, Asia (China, Japan, Hong Kong, and India), and Latin America (Argentina and Brazil). I also have a strong business development background, holding degrees from Harvard Business School and the University of California San Francisco School of Medicine, and being certified for clinical research. My mission is to rewrite the future of genomic medicine and improve the lives of millions of patients worldwide.
Listed skills include Clinical Development, Clinical Trials, Pharmaceutical Industry, Clinical Research, and 34 others.
Current workplace
Alvin Luk's current company
Company context helps verify the profile and gives searchers a useful next step.
19 roles · 34 years
Alvin Luk work experience
A career timeline built from the work history available for this profile.
Co-Founder And Ceo
CurrentHuidaGene Therapeutics (辉大基因) is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing CRISPR-based gene-editing tools and gene therapies to rewrite the future of genomic medicine. The robust pipeline covering CNS, ophthalmology, myology, otology, hepatology and novel technologies include:CNS:- HG204: RNA.
May 2023 - Present
Member Of Scientifc Advisory Board
CurrentA global clinical-stage biotech company focusing on discovering, engineering, and developing CRISPR-based gene therapy to rewrite the future of genome medicine. Product pipeline includes RPE65-associated inherited retinal dystrophies, neovascular age-related macular degeneration, retinitis pigmentosa, hereditary hearing loss, Duchenne muscular dystrophy.
Apr 2023 - Present
Member Board Of Directors
Current
Apr 2023 - Present
Global Drug Development Advisor
Current-Global drug development strategist with more than 30 years of biotech/pharmaceutical experience in multi-portfolio management (antibodies, protein biologics, biosimilars, and gene therapy) to define strategic planning and pipeline growth.-Former member at the industrial board of the US FDA Rare Disease Clinical Design Committee.-Key core members to win.
1992 - Present
~34 yrs 5 mos
Apr 1991 - 1998
Member Board Of Directors
Current
Jun 2022 - Present
Member Scientific Advisory Board
Current
May 2022 - Present
Member Board Of Directors
May 2020 - Apr 2022
Chief Executive Officer
Our mission is to discover and develop AAV2 gene therapies for ocular diseases.
Apr 2020 - Apr 2022
Senior Drug Development And Strategy Advisor
Developing AAV-gene therapy product candidates for the treatment of genetic ocular diseases.
Aug 2019 - Apr 2020
Global Clinical And Medical Affairs Advisor
A global role that is responsible for delivering strategic clinical programs, driving operational efficiencies, implementing business change and expanding R&D portfolio by in-/out-licensing evaluations.- HLX10 in sNSCLC- HLX10 in SCLC- HLX10 + HLX04 (bevacizumab biosimilar) in HCC- HLX04 (bevacizumab biosimilar) for wAMD and DME
May 2020 - Aug 2021
Chief Medical Officer And Senior Vp Of Global Clinical And Medical Affairs (Gcma)
A. Biosimilars (Oncology and Immunology) - rituximab (approved on 2/2019 in China; 汉利康® /HanLiKang) - trastuzumab (approved on 8/2020 in China - 汉曲优®, approved on 7/2020 in EU - Zercepac®, and approved on 4/2024 in US - HERCESSI™) - adalimumab (approved on 12/2020 in China - 汉达远® /HanDaYuan) - bevacizumab (approved on 11/2022 in China - 汉贝泰® /HanBeiTai).
2017 - Apr 2020
Head Of Clinical Research And Operations (Vp-Level)
- AAV Gene Therapy for Rare Genetic Diseases- SPK9001 - Hemophilia B -collaboration with Pfizer (BEQVEZ)- SPK8011 - Hemophilia A- SPK-7001 - Choroideremia- Batten (CLN-2) Disease- Huntington's Disease
2014 - 2017
~3 yrs
Senior Director, Global Medical Affairs & Group Head/Sr Director, Clinical Development Operations
Global Medical Affairs- Eloctate (recombinant factor VIII Fc-fusion protein for patients with hemophilia A: from BLA submission to FDA approval and launch)- Alprolix (recombinant factor IX Fc-fusion protein for patients with hemophilia B: from BLA submission to FDA approval and launch)Global Clinical Development Operations-Recombinant factor VIII Fc-fusion.
2009 - 2014
~5 yrs
Industrial Board Member
FDA-Rare disease clinical design committee: Focusing on optimizing clinical trial design for rare diseases to shorten drug development timeline
2006 - 2009
~3 yrs
Deputy Director, Global Clinical Development Operations And Program Management (Gcdop)
- Extended half-life coagulation factor VIII product development: a. Liposomal-BAY-79-4980 b. PEGylated-BAY-94-9027, Jivi- Life-cycle management of Kogenate (expanded label indication of Kogenate-FS for "children prophylaxis" and BAY 81-8973, Kovaltry)- Supports in China and South East Asia Kogenate-FS launches- In-licensing review of recombinant Thrombin.
2005 - 2009
~4 yrs
Associate Director, Clinical Development & Operations (Pd/Hemophilia/Neuropathic Pain/Gene Therapy)
- Adeno-associated vector serotype 2 (AAV2) encoding human coagulation factor IX (FIX) for hemophilia B- Adeno-associated vector serotype 2 (AAV2) encoding human aromatic L-amino acid decarboxylase (AADC) for parkinson disease- AV-411 for neuropathic pain
2002 - 2005
~3 yrs
Strategic Portfolio & Project Management
Identifying lead candidates using LxxLL-motif agonist and antagonist of orphan nuclear receptors screening which acted through the regulation of gene expression:a. PPARa,b,d and -g (peroxisome proliferator-activated receptors)b. ERRa, b and -g (estrogen-related receptors)c. RXRa, b and -g (9-cis retinoic acid receptors)d. NURR1 (nuclear receptor related-1.
1998 - 2002
~4 yrs
4 education records
Alvin Luk education
Master Of Business Administration - Mba, Business Administration
Harvard Business School
Clinical Research
University Of California, San Francisco - School Of Medicine
Doctor Of Philosophy - Phd, Neurobiology And Neurosciences
University Of California, San Francisco
Cell/Cellular And Molecular Biology And Physiology
University Of California, Berkeley
FAQ
Frequently asked questions about Alvin Luk
Quick answers generated from the profile data available on this page.
What company does Alvin Luk work for?
Alvin Luk works for HuidaGene Therapeutics.
What is Alvin Luk's role at HuidaGene Therapeutics?
Alvin Luk is listed as Co-Founder and CEO at HuidaGene Therapeutics.
What is Alvin Luk's email address?
AeroLeads has found 1 work email signal at @peoplepc.com for Alvin Luk at HuidaGene Therapeutics.
What is Alvin Luk's phone number?
AeroLeads has found 2 phone signal(s) with area code 415 for Alvin Luk at HuidaGene Therapeutics.
Where is Alvin Luk based?
Alvin Luk is based in New York, New York, United States while working with HuidaGene Therapeutics.
What companies has Alvin Luk worked for?
Alvin Luk has worked for Huidagene Therapeutics, Biotech Industry, Hanchorbio Inc. 漢康生技股份有限公司, Biotech, and Neurophth Therapeutics / 纽福斯生物科技有限公司.
How can I contact Alvin Luk?
You can use AeroLeads to view verified contact signals for Alvin Luk at HuidaGene Therapeutics, including work email, phone, and LinkedIn data when available.
What schools did Alvin Luk attend?
Alvin Luk holds Master Of Business Administration - Mba, Business Administration from Harvard Business School.
What skills is Alvin Luk known for?
Alvin Luk is listed with skills including Clinical Development, Clinical Trials, Pharmaceutical Industry, Clinical Research, Gcp, Biotechnology, Cro, and Medical Affairs.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial